GH Research (NASDAQ:GHRS) Stock Price Up 0.1% – Should You Buy?

GH Research PLC (NASDAQ:GHRS) shot up 0.1% on Friday . The company traded as high as $9.73 and last traded at $8.98. 44,624 shares traded hands during trading, a decline of 44% from the average session volume of 79,020 shares. The stock had previously closed at $8.97.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th.

GH Research Stock Up 1.3 %

The firm’s fifty day moving average price is $7.76 and its 200-day moving average price is $10.37. The stock has a market cap of $472.93 million, a P/E ratio of -11.51 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. Sell-side analysts predict that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP increased its stake in GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,310,563 shares of the company’s stock after buying an additional 1,471,946 shares during the period. GH Research accounts for 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th largest position. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).